Ignite Creation Date:
2024-05-05 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00481663
Status:
COMPLETED
Last Update Posted:
2017-04-04
First Post:
2007-06-01
Brief Title:
A Study of Different Doses of Sitagliptin MK-0431 in Participants With Type 2 Diabetes Mellitus MK-0431-014
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Multicenter Double-Blind Randomized Placebo-Controlled Dose-Ranging Finding Study of Once-Daily Dosing of Sitaglipin MK-0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study of different doses of MK-0431 in participants with type 2 diabetes mellitus There have been 3 extensions to the base study Extension 1 up to Week 52 Extension 2 up to Week 106 and Extension 3 up to Week 158 The primary hypothesis for the study is that In participants with type 2 diabetes who have inadequate glycemic control after 12 weeks of treatment a dose-response will be seen across once-daily doses of MK-0431 in lowering hemoglobin A1C HbA1c
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2007_570 | None | None | None |